- Cell therapy company Chimeric Therapeutics (CHM) expands a license agreement for its antigen receptor therapies with the University of Pennsylvania
- Under the amended deal, Chimeric will acquire a non-exclusive, “know-how license” to use Penn’s third-generation lentiviral vector plasmid system for the development and commercialisation of CHM 2101
- This amended license will allow Chimeric to manufacture clinical-grade lentiviral vector for use in its phase one study for treating gastrointestinal (stomach) cancers
- The upfront licensing fee will be funded through Chimeric’s existing cash reserves
- Chimeric Therapeutics last traded at 9.2 cents on June 28
Chimeric Therapeutics (CHM) has expanded a license agreement for its antigen receptor therapies.
The clinical-stage cell therapy company agreed to increase its agreement with the University of Pennsylvania (Penn), which was first penned in July 2021.
Under the amended deal, Chimeric will acquire a non-exclusive, “know-how license” to use Penn’s third-generation lentiviral vector plasmid system for the development and commercialisation of Chimeric’s CHM 2101.
This amended license will enable Chimeric to manufacture clinical-grade lentiviral vector for use in its phase one study of CHM 2101 for treating gastrointestinal cancers.
The vector is a component used in the manufacturing of CAR T cells, with the third-generation lentiviral vectors are said to offer improved safety over previous generations.
CHM 2101 is currently in preclinical development, and is being investigated through a planned trial in neuroendocrine tumours, colorectal, gastroesophageal and gastric cancer.
The deal will also allow Chimeric to cross-reference regulatory information on file with the US Food and Drug Administration to facilitate filing of an investigational new drug (IND) for CHM 2101.
The upfront licensing fee will be funded through Chimeric’s existing cash reserves.
Chimeric Therapeutics last traded at 9.2 cents on June 28.